AOD-9604
Research Use Only | Not for Human Consumption
A synthetic 16-amino-acid fragment corresponding to residues 176u2013191 of the C-terminus of human growth hormone
AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone (HGH), corresponding to amino acids 176u2013191. It has been examined in preclinical models for interactions with lipolytic signaling pathways distinct from the glycemic and growth-promoting pathways associated with full-length HGH.
| CAS# | Formula | Molar Mass |
|---|---|---|
| 221231-10-3 | C₇₈H₁₂₃N₂₃O₂₃S₂ | 1815.08 g/mol |
All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.
A synthetic fragment of human growth hormone (residues 176–191)
What is AOD-9604?
AOD-9604 was developed in the late 1990s at Monash University in Australia. Researchers there were investigating whether a fragment of the growth hormone molecule could retain lipolytic signaling activity in adipocyte models without the glycemic and proliferative effects of the full-length protein.
The team identified that amino acids 176 to 191 of the growth hormone sequence exhibited lipolytic signaling in adipose tissue models without activating insulin or IGF-1-related growth pathways. They designated this fragment AOD-9604.
AOD-9604 has appeared in peer-reviewed preclinical publications examining growth-hormone fragment biology and adipocyte signaling since the early 2000s. This product is intended for research use only.
What is AOD-9604 studied for?
The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.
Lipolysis Pathway Research
In preclinical adipocyte models, AOD-9604 has been investigated for interactions with lipolytic signaling in adipose tissue.
View Studies (1)Fatty-Acid Oxidation Research
In preclinical models, AOD-9604 has been examined for observations related to fatty-acid oxidation and metabolic-rate parameters.
View Studies (1)Lipogenic Enzyme Research
In vitro studies have examined AOD-9604's interactions with lipogenic enzyme activity and triglyceride accumulation in adipocytes.
View Studies (1)Glucose & Insulin Pathway Research
In laboratory models, AOD-9604 has been examined for interactions with glucose metabolism and insulin signaling pathways relative to full-length growth hormone.
View Studies (1)Mitochondrial Beta-Oxidation Research
In preclinical studies, AOD-9604 has been examined for interactions with mitochondrial fatty-acid oxidation pathways.
View Studies (1)Adipose Tissue & Lipid Profile Research
In preclinical models, AOD-9604 has been examined for associations between visceral adipose tissue markers and lipid profile parameters.
View Studies (1)How should AOD-9604 be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.
After reconstitution, the peptides will remain stable for up to 30 days.
Certificate of Analysis
All AOD-9604 batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.
HPLC Purity
—
No Certificate of Analysis is available for the selected size yet. Contact support for batch-specific documentation.
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Related Research Compounds
Frequently purchased with AOD-9604
Add all 3 items to your cart
$275
Clinical References
- Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and u03b23-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PubMed: 11713213
- Ng FM, et al. Growth hormone treatment of hypophysectomized rats increases the secretion of insulin-like growth factor-I. Endocrinology. 2000;141(8):3098-3103. PubMed: 10965879
- Munro S, et al. AOD9604, a synthetic lipolytic peptide with high receptor binding affinity and in vivo efficacy. International Journal of Obesity. 2006;30(8):1217-1224.
